Xilio Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $43.8M | $6.3M | — | — | — |
| Research and development | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M |
| Operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Pretax income | -$35.0M | -$58.2M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| Balance Sheet | |||||
| Cash and equivalents | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M |
| Current assets | $145.0M | $60.2M | $48.1M | $124.5M | $202.5M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Current liabilities | $56.3M | $27.3M | $16.0M | $21.1M | $12.8M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Stockholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Depreciation and amortization | $1.5M | $1.6M | $1.9M | $1.8M | $1.5M |
| Stock-based compensation | $6.9M | $6.4M | $7.4M | $8.4M | $5.0M |
| Capital expenditure | $518,000 | $36,000 | $486,000 | $1.9M | $1.1M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
Shares outstanding 5.8M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.